NCT02882659View on ClinicalTrials.gov

Dendritic Killer Cell-based Immunotherapy for Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

December 31, 2017

Conditions
Colorectal NeoplasmsHepatocellular CarcinomaNeoplasm Metastasis
Interventions
BIOLOGICAL

Dendritic Killer Cell (DKC)

DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.

Sponsors
All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

lead

FullHope Biomedical Co., Ltd.

INDUSTRY